Goldman Sachs raises Rhythm Pharmaceuticals stock price target on HO launch outlook
PositiveFinancial Markets

Goldman Sachs has raised its price target for Rhythm Pharmaceuticals, reflecting optimism about the company's upcoming HO launch. This adjustment signals confidence in Rhythm's potential to deliver innovative treatments, which could significantly impact the market and improve patient outcomes. Investors are likely to view this as a positive development, indicating a strong future for the company.
— Curated by the World Pulse Now AI Editorial System